Our Story2018-10-10T17:27:50+00:00

We bring genetics to everyday life

Our Story

In a time of unparalleled advancement in genetic research, many people have yet to access the benefits of genomic medicine. Genome Medical was created to change that, by ensuring the lifelong journey of genomic medicine becomes accessible to everyone.

We are a nationwide genomics medical practice bringing genetics to everyday life. Our clinical team provides expert genetic health care for individuals and families to improve health and well-being. We also help clinicians and patients navigate the rapidly expanding field of genetic testing and use test results to understand disease risk, speed diagnosis, make informed treatment decisions and lower the cost of care.

Genome Medical was founded in 2016 by genetics industry leaders Lisa Alderson, MBA; Randy Scott, PhD, executive chairman of Invitae and founder of Genomic Health; and Robert C. Green, MD, MPH, a medical geneticist who directs the Genomes2People Research Program at Brigham and Women’s Hospital, is an associate member of the Broad Institute and is professor of medicine at Harvard Medical School.

Lisa has 20 years of experience building early-stage companies with a focus on technology, consumer and life sciences businesses. Prior to Genome Medical, Lisa served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was part of the start-up team at Genome Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc. and the former manager of strategic planning at The Walt Disney Co.

Lisa Alderson
Co-founder and Chief Executive Officer

Randy is Chairman of Invitae, a company he co-founded and where he previously served as CEO. He also founded Genomic Health and served as Genomic Health’s Chief Executive Officer from 2000 until 2009 and Executive Chairman until 2012. Under Randy’s leadership, Genomic Health developed and launched two revolutionary cancer diagnostics tests. At Incyte, Randy served in various roles from 1991 through 2000, including Chairman of the Board, President and Chief Scientific Officer.

Randy Scott, PhD
Co-founder and Chairman

Dr. Green is co-founder and chairman of Genome Medical’s Scientific Advisory Board. He is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School. Dr. Green is principal investigator of the MedSeq Project, the first NIH-funded randomized trial to explore the use of whole genome sequencing in the clinical practice of medicine.

Robert Green, MD, MPH

Our Leadership Team

Lisa has 20 years of experience building early-stage companies with a focus on technology, consumer and life sciences businesses. Prior to Genome Medical, Lisa served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was part of the start-up team at Genome Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc. and the former manager of strategic planning at The Walt Disney Co.

Lisa Alderson
Co-founder and Chief Executive Officer

Steve is board-certified in medical genetics with a doctorate degree in human genetics and background experience spanning clinical care, academic research and oversight of clinical services across an integrated health system. Prior to this role, he directed the Clinical Genetics Institute (CGI) for Intermountain Healthcare, where he oversaw provision of genetic services, implementation of genetic testing stewardship and development of a system-wide infrastructure for storage and use of genomic data. Dr. Bleyl maintains an academic affiliation with the University of Utah, where his clinical practice focuses on cardiovascular genetics.

Steven B. Bleyl, MD, PhD
Chief Medical Officer

Murielle is a seasoned health care executive with experience spanning payor, provider, supply chain, biopharma and health IT companies. She was most recently Executive in Residence for GE Healthcare Ventures. Prior to that, Murielle served as vice president and general manager for several departments at McKesson Specialty from generics distribution, group purchasing organization to analytics decision support tools for oncology practices. She has also held positions in strategy, marketing and operations at Novartis, Genentech, and UnitedHealth/OptumHealth. Murielle has an MBA from the Wharton School and a master’s degree in finance from Université Jean Moulin in her native Lyon, France.

Murielle Thinard McLane
Chief Operating Officer

Sandra has more than 20 years in finance and strategy for venture-backed companies. Prior to Genome Medical, she served as interim CFO for Glooko, a diabetes information management SaaS solution. Previously, as CFO, she ushered two consecutive biotech companies from start-up to acquisition by public companies (Ligand Pharmaceuticals (NASDAQ: LGND and Roche Holdings AG “RHHBY”).

Sandra Cavanagh
Chief Financial Officer

Erynn is a board-certified genetic counselor with expertise in clinical care, research and laboratory genetics. A leader in the genetic counseling community, Erynn has served as President of the American Board of Genetic Counseling and on the National Society of Genetic Counselors Board of Directors. Prior to joining Genome Medical, Erynn was the first genetic counselor at 23andMe, serving as Director of Clinical Affairs. She previously managed a precision medicine study at at the Coriell Institute for Medical Research and held clinical roles at University of Maryland School of Medicine and Children’s National Medical Center.

Erynn Gordon, MS, LCGC
Vice President of Clinical Operations

Vineet is a seasoned Silicon Valley engineering leader with 20 years of building high-performing teams and products. His domain expertise ranges from search engines, storage appliances, network security, cloud computing to cybersecurity and AI. He has a successful track record in taking engineering-driven startups through IPO (Fireeye) and acquisition (Cisco/Virtuata). Building engineering teams from ground up and then scaling them geographically and functionally to meet growing customer demands are recurrent themes in his career.

Vineet Kumar
Vice President of Engineering

Romy has a background in health care operations and a passion for enabling access to the highest quality of care for all. Prior to Genome Medical, Romy was a Regional Operations Director at Davita. She previously held several positions at non-profits focused on HIV, AIDS and global health in the United States and East Africa. Romy has an MBA from the Stanford University Graduate School of Business.

Romy Saloner
Vice President of Operations

Bill has worked in health care communications and marketing for more than 20 years. He joined Genome Medical from 23andMe, where he was the Senior Manager for Commercial Marketing. Previously, Bill worked at ZEISS Medical Technology on the global communications team, and he also served as Director of Communications at the American Academy of Ophthalmology.

Bill Taggart
Director of Marketing

Our Investors

Genome Medical is privately funded. Its Series A funding was led by Canaan Partners with investors Flywheel Ventures, HealthInvest Equity Partners and Illumina Ventures. GE Ventures led the second round of funding, with new strategic investor Kaiser Permanente Ventures joining and additional investments from Canaan Partners and Illumina Ventures.

“The Genome Medical team’s vision and experience are unmatched. Their commitment to bringing genomic medicine into mainstream health care in a medically responsible way has the potential to transform the next chapter of medicine.”

— Stephen Bloch, General Partner, Canaan Partners

Genome Medical